

The selection and use of essential in vitro diagnostics

Report of the second meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics, 2019
(including the second WHO model list of essential in vitro diagnostics)



The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The WHO *Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int; order on line: www.who.int/bookorders).

W H O T e c h n i c a l R e p o r t S e r i e s
1 0 2 2

The selection and use of essential in vitro diagnostics

Report of the second meeting of the WHO Strategic Advisory Group of
Experts on In Vitro Diagnostics, 2019
(including the second WHO model list of essential in vitro diagnostics)



**World Health
Organization**

The selection and use of essential in vitro diagnostics: report of the second meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics, 2019 (including the second WHO model list of essential in vitro diagnostics).

(WHO Technical Report Series, No. 1022)

ISBN 978-92-4-121031-7

ISSN 0512-3054

© World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. The selection and use of essential in vitro diagnostics: report of the second meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics, 2019 (including the second WHO model list of essential in vitro diagnostics). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1022). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Printed in Italy

Contents

| | |
|--|------|
| Abbreviations and acronyms | v |
| List of participants | vii |
| Declarations of interests of the Strategic Advisory Group of Experts on In Vitro Diagnostics (SAGE IVD), observers, reviewers and consultants | xi |
| Acknowledgements | xii |
| Executive summary | xiii |
| 1. Introduction | 1 |
| 2. Open session | 2 |
| 3. General items | 7 |
| 3.1 Methods used to establish the second EDL | 7 |
| 3.1.1 Changes to entries in the first EDL | 8 |
| 3.1.2 Submissions for new product categories | 8 |
| 3.1.3 Proposals for general and anatomical pathology tests | 10 |
| 3.1.4 Proposal for inclusion of therapeutic drug monitoring tests | 10 |
| 3.1.5 Public consultation | 11 |
| 3.1.6 Process for decision-making | 11 |
| 3.2 Changes to the structure of the List | 11 |
| 3.3 Country implementation plans | 12 |
| 3.4 Integration of the List within other WHO initiatives | 13 |
| 3.4.1 Integration with the Essential Medicines List | 13 |
| 3.4.2 Integration with the WHO Expert Committee on Biological Standardization | 14 |
| 3.5 Eligibility for prequalification | 14 |
| 4. Summary of recommendations | 16 |
| 4.1 General recommendations | 16 |
| 4.2 Additions to the List | 20 |
| 4.3 Deletions from the List | 25 |
| 4.4 Changes to listings | 25 |
| 4.5 Rejected proposed changes | 25 |
| 4.6 Rejected applications | 28 |
| 5. Accepted applications for the second Model List of Essential In Vitro Diagnostics | 29 |
| Section I.b. Disease-specific tests for use in community settings and health facilities without laboratories | 29 |
| <i>Leishmania</i> rk39 antigen: rapid diagnostic test | 29 |
| <i>Vibrio cholerae</i> antigen: rapid diagnostic test | 33 |
| Section II.a General in vitro diagnostics for clinical laboratories | 38 |
| Clinical chemistry | 38 |
| Procalcitonin in serum and plasma: immunoassay | 38 |
| Section II.b Disease-specific in vitro diagnostics for clinical laboratories | 43 |
| Cancer | 43 |
| Alpha fetoprotein immunoassay for diagnosis of liver and germ-cell tumours | 43 |

| | |
|---|-----|
| Basic panel of immunohistochemical tests for diagnosis of lymphoma | 48 |
| Basic panel of immunohistochemical tests for diagnosis of solid tumours | 53 |
| <i>BCR-ABL1</i> and <i>ABL1</i> transcripts for diagnosis of chronic myelogenous leukaemia (CML) and CML variants and prognosis of acute lymphoblastic leukaemia (ALL) | 57 |
| Essential panel of antibodies for flow cytometry for leukaemia | 62 |
| Faecal immunochemical test (FIT) for screening for colorectal cancer | 66 |
| Guaiac faecal occult blood test | 71 |
| Human chorionic gonadotrophin plus β -human chorionic gonadotrophin immunoassay to aid in the diagnosis of and surveillance for germ-cell tumours and gestational trophoblastic disease | 76 |
| Human epidermal growth factor receptor 2 (HER2) or tyrosine-protein kinase receptor (erbB-2) or overexpression: immunohistochemical tests to aid in diagnosis, prognosis and treatment of breast cancer | 80 |
| Lactate dehydrogenase activity to aid in the prognosis and monitoring of haematological malignancies and germ-cell tumours | 84 |
| Oestrogen and progesterone receptors in breast cancer: immunohistochemical test | 88 |
| Papanicolaou smear test | 92 |
| Prostate-specific antigen | 96 |
| HIV infection | 100 |
| Histoplasma antigen enzyme immunoassay | 100 |
| Influenza | 104 |
| Influenza antigen: rapid immunoassay to aid in diagnosis of seasonal influenza | 104 |
| Influenza A and B: nucleic acid test for diagnosis of seasonal influenza | 108 |
| Neglected tropical diseases | 112 |
| Dengue virus antibody enzyme immunoassay or rapid diagnostic test | 112 |
| Dengue virus antigen (NS1) enzyme immunoassay or rapid diagnostic test | 116 |
| Dengue virus nucleic acid test | 120 |
| Kato-Katz test for soil-transmitted helminths and intestinal schistosomes | 125 |
| Primary immunodeficiency disorders | 128 |
| Lymphocyte subtypes (CD4, CD8, CD20 and CD16/56 cells, B cells and NK cells) | 128 |
| Plasma levels of immunoglobulins G, A and M | 133 |
| Plasma and urine protein electrophoresis and immunofixation | 138 |
| Response to tetanus and pneumococcus vaccines | 143 |
| Sexually transmitted infections | 147 |
| <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> genomic DNA | 147 |
| <i>Treponema pallidum</i> antibodies: rapid diagnostic test for diagnosis or as an aid in diagnosis of syphilis | 151 |
| Zika virus infection | 154 |
| Zika virus: enzyme-linked immunoassay for immunoglobulin M | 154 |
| Test for Zika virus nucleic acid | 158 |

Annex 1

| | |
|---|-----|
| Second Model List of Essential In Vitro Diagnostics (EDL) | 163 |
|---|-----|

Index

| | |
|--|-----|
| | 215 |
|--|-----|

Abbreviations and acronyms

| | |
|-------|---|
| AFP | alpha-fetoprotein |
| ALL | acute lymphoblastic leukaemia |
| CML | chronic myelogenous leukaemia |
| DALY | disability-adjusted life-year |
| DENV | dengue virus |
| ECLIA | electrochemiluminescence immunoassay |
| EDL | Essential In Vitro Diagnostics List |
| eEDL | electronic EDL |
| EIA | enzyme immunoassay |
| ELISA | enzyme-linked immunosorbent assay |
| EML | Essential Medicines List |
| ER | oestrogen receptor |
| FDA | Food and Drug Administration (USA) |
| FIT | faecal immunochemical test |
| gFOBT | guaiac faecal occult blood test |
| hCG | human chorionic gonadotrophin |
| HER2 | human epidermal growth factor receptor 2 |
| HPV | human papillomavirus |
| IARC | International Agency for Research on Cancer |
| Ig | immunoglobulin |
| IHC | immunohistochemistry |
| IHR | International Health Regulations (2005) |
| IPOPI | International Patient Organisation for Primary Immunodeficiencies |
| IU | international units |
| IVD | in vitro diagnostic |
| LDH | lactate dehydrogenase |
| LMICs | low- and middle-income countries |

| | |
|--------|---|
| NAAT | nucleic acid amplification test |
| NAT | nucleic acid test |
| NGO | nongovernmental organization |
| PCR | polymerase chain reaction |
| PgR | progesterone receptor |
| PHC | primary health care |
| PHEIC | public health emergency of international concern |
| PSA | prostate-specific antigen |
| QALY | quality-adjusted life-year |
| RDT | rapid diagnostic test |
| RT-PCR | reverse transcriptase PCR |
| SAGE | Strategic Advisory Group of Experts |
| TPHA | <i>Treponema pallidum</i> haemagglutination assay |
| TPPA | <i>Treponema pallidum</i> particle agglutination |
| UHC | universal health coverage |
| VDRL | Venereal Disease Research Laboratory |
| ZIKV | Zika virus |

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/repor>